To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

August 08, 2018

Today's Rundown

Featured Story

Liver-focused Ambys launches with $140M, Takeda partnership

Third Rock Ventures is debuting Ambys Medicines, which will develop cell and gene therapies as well as drugs for chronic liver diseases. It starts out with $100 million in committed capital from Takeda, part of which came in the startup’s $60 million series A round.

Top Stories

SQZ raises $72M as cell therapies close in on clinical trials

SQZ Biotechnologies has raised $72 million. The series C round sets the Roche-partnered MIT spinout to advance cell therapy treatments of solid tumors and autoimmune diseases toward the clinic.

Quick-fire fundraisings give Apexigen $73M for I-O push

Apexigen has raised $73 million from a pair of financings that will be used for clinical testing of its lead CD40-targeting immuno-oncology candidate as well as to broaden its pipeline.

Regenxbio’s wet AMD gene therapy shows promise in phase 1

Regenxbio's gene therapy for wet age-related macular degeneration (AMD) reduced the need for in-eye injections of anti-VEGF drugs. The company is now looking to move the treatment into phase 2.

Boston Scientific acquires remainder of vein stent maker Veniti in $160M deal

Boston Scientific plans to fully acquire stent developer Veniti—which it already owns 25% of—by buying up the remaining stake in the startup for $108 million upfront, plus up to $52 million pending FDA approval of its Vici system for vein obstructions.

Resources

[Whitepaper] Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure.

[Whitepaper] HOW TO POSITION YOUR PATIENT SUPPORT PROGRAM FOR SUCCESS

When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients.

[Whitepaper] Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites

Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals.

[Survey] Industry Report: Findings from the 2018 Unified Clinical Operations Survey

Industry Research: See new results from one of the industry's largest, global clinical operations surveys.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[Whitepaper] Rise in Targeted Therapies Drives Needs for Small Volume Manufacturing

Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy.

[Whitepaper] eClinical Landscape Study - CRO Report from Tufts Center for the Study of Drug Development

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs).

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.